Meng Ding > Sidley Austin > Hong Kong, Hong Kong > Lawyer Profile
Sidley Austin Offices
LEVEL 39, TWO INTERNATIONAL FINANCE CENTRE
8 FINANCE STREET, CENTRAL
HONG KONG
Hong Kong
- Firm Profile
- Go to...
Meng Ding
Work Department
China Corporate and Finance
Position
Partner
Career
Meng Ding has extensive experience counselling issuers and investment banks on a broad spectrum of capital markets and M&A transactions. He focuses on Greater China and Asia companies, frequently advising on transactions that define their growth and success, from early-stage financing to listing to post-listing matters.
He has advised on numerous Hong Kong IPOs, U.S. IPOs and bond offerings, including some of Greater China’s largest, most complex and precedent-setting transactions. Meng is renowned for his ground-up approach to gain deep understanding of industries, ranging from e-commerce platforms to specialist hard-tech companies to life science and pharmaceutical firms to financial institutions.
Meng received a Ph.D. in physics from M.I.T. Earlier in his career, he was a Silicon Valley technologist, innovating at semiconductor powerhouses like IBM and AMD. He holds 32 issued U.S. patents. He remains a technology enthusiast ever since and stays closely connected to the tech community, particularly in Greater China. These special knowledge and experience distinguish him when advising technology issuers, especially hard-tech and deep-tech companies, where insights and in-depth expertise are essential to understand their technology roadmap, product evolution and industry landscape.
Lawyer Rankings
Hong Kong > Capital markets (equity)
(Leading partners)Positioning itself very much at the forefront of the new economy space, the ‘technically strong’ team at Sidley Austin
delivers ‘high-quality work’ for an issuer-focused client base seeking to list on the HKEX. The team has been at the vanguard of the new listing rules affecting both pre-revenue healthcare and specialist tech companies, having had a key role in actually shaping the 18C listing rules through its interactions with the regulator. The ‘very commercial’ Claudia Yu, who is ‘particularly capable at advising on novel rules and pioneer transactions’, has been key to much of this work, including her lead role for QuantumPharm Inc., in what is the first specialist technology company expected to list under the new Chapter 18C. Himself a former scientist, Meng Ding has deep industry understanding and is also key to much of this work, excelling in drafting the underlying prospectuses. The ‘technical, commercial and responsive’ Sherlyn Lau is also key to the firm’s growing success and co-heads team alongside Constance Choy.